Brandon Trumble
Family · Springfield, MONPI 1972932853
Payments from drug & device makers
Across 387 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$996
- Otsuka America Pharmaceutical, Inc.$602
- Neurocrine Biosciences, Inc.$488
- Indivior Inc.$479
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$425
- Teva Pharmaceuticals USA, Inc.$408
- plus $3K from 25 others
What the payments were for
- Food & beverage$6,20799%
- Education$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $996 |
| Otsuka America Pharmaceutical, Inc. | 44 | $602 |
| Neurocrine Biosciences, Inc. | 21 | $488 |
| Indivior Inc. | 26 | $479 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $425 |
| Teva Pharmaceuticals USA, Inc. | 37 | $408 |
| E.r. Squibb & Sons, L.L.C. | 21 | $374 |
| Pfizer | 35 | $314 |
| Alkermes, Inc. | 16 | $302 |
| Viiv Healthcare Company | 14 | $277 |
| Corium, LLC | 10 | $215 |
| Johnson & Johnson | 10 | $209 |
| Lundbeck LLC | 10 | $186 |
| Collegium Pharmaceutical, Inc. | 11 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $119 |
| Braeburn Inc. | 6 | $116 |
| Axsome Therapeutics, Inc. | 4 | $94 |
| Merck | 5 | $74 |
| Supernus Pharmaceuticals, Inc. | 4 | $67 |
| Ironshore Pharmaceuticals Inc. | 3 | $52 |
| Avanir Pharmaceuticals, Inc. | 3 | $50 |
| Protega Pharmaceutials Inc | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Avion Pharmaceuticals | 1 | $28 |
| Gilead | 1 | $24 |
| Almatica Pharma LLC | 1 | $23 |
| Dexcom, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Vertex | 1 | $19 |
| Exact Sciences | 1 | $15 |
How this compares
$6,260 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 29 | $45,820 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 264 | $43,452 |
| VraylarCariprazine Hcl | 27 | $40,492 |
| OzempicSemaglutide | 28 | $38,011 |
| TrulicityDulaglutide | 25 | $26,635 |
| TrintellixVortioxetine Hydrobromide | 29 | $18,820 |
| FarxigaDapagliflozin Propanediol | 30 | $17,633 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,932 |
| JardianceEmpagliflozin | 16 | $14,751 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 20 | $13,964 |
| SymbicortBudesonide/Formoterol Fumarate | 55 | $13,421 |
| Spiriva RespimatTiotropium Bromide | 22 | $12,397 |
| Spiriva HandihalerTiotropium Bromide | 23 | $11,617 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 13 | $10,595 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $9,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess | $996 | $47,45640 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $602 | $45,82029 claims |
| Lilly USA, LLCTrulicity | $20 | $26,63525 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $119 | $18,82029 claims |
| Indivior Inc.Suboxone | $479 | $13,96420 claims |
| Johnson & JohnsonInvokana | $209 | $7,83013 claims |
| MerckBelsomra | $74 | $5,11112 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $408 | $1,96431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.
Other family in Springfield
- Laura HedigerSpringfield$71K
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.